The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

We recently published a list of Top 10 Stocks to Buy According to Two Sigma Investments. In this article, we are going to ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

According to Direxion CEO Douglas Yones, Eli Lilly and Palo Alto Networks are prime candidates for leveraged trading.

The Hyderabad center is expected to be operational by mid-2025 and will be Lilly’s second capability center in India after ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

This was the stock's second consecutive day of losses.

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...

We recently published a list of 10 Best Stocks to Buy Now For the Long Term. In this article, we are going to take a look at ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...